Interdisciplinary Laboratory of Clinical Analysis, Interlab-UMU, Regional Campus of International Excellence 'Campus Mare Nostrum', University of Murcia, 30100 Murcia, Spain.
Unit of Microbiology, Hospital General Universitario Reina Sofía, Universidad de Murcia, 30003 Murcia, Spain.
Int J Environ Res Public Health. 2021 Dec 21;19(1):41. doi: 10.3390/ijerph19010041.
High ferritin serum levels can be found in patients with macrophage activation syndrome, and increased serum ferritin due to cytokine storm have been reported in severe COVID-19 patients. Saliva is being increasingly used in COVID-19 tests as a diagnostic sample for virus detection and quantification. This study aimed to evaluate the possible changes in ferritin in saliva in COVID-19 patients. In addition, the effects of different inactivation SARS-CoV-2 treatments in ferritin measurements in saliva, the correlation between ferritin in saliva and serum, and the possible effects of correction of ferritin values by total protein were assessed. Ferritin was measured in saliva from healthy ( = 30) and COVID-19 ( = 65) patients with severe, ( = 18) or mild ( = 47) disease, depending on the need for nasal flow oxygen or assisted respiration. Ferritin was also measured in paired serum and saliva samples ( = 32) from healthy and COVID-19 patients. The evaluated inactivation protocols did not affect the assay's results except the addition of 0.5% SDS. Significantly higher ferritin was found in the saliva of COVID-19 patients (median; 25-75th percentile) (27.75; 9.77-52.2 µg/L), compared with healthy controls (4.21; 2.6-8.08 µg/L). Individuals with severe COVID-19 showed higher ferritin values in saliva (48.7; 18.7-53.9) than mild ones (15.5; 5.28-41.3 µg/L). Significant correlation (r = 0.425; < 0.001) was found between serum and saliva in ferritin. Ferritin levels were higher in COVID-19 patients in serum and saliva, and the highest values were found in those patients presenting severe symptomatology. In conclusion, ferritin in saliva has the potential to be a biomarker to evaluate severity in patients with COVID-19.
高血清铁蛋白水平可见于巨噬细胞活化综合征患者,且有研究报道重症 COVID-19 患者因细胞因子风暴而出现血清铁蛋白升高。唾液在 COVID-19 检测中越来越多地被用作病毒检测和定量的诊断样本。本研究旨在评估 COVID-19 患者唾液中铁蛋白可能发生的变化。此外,还评估了不同 SARS-CoV-2 灭活处理对唾液中铁蛋白检测的影响、唾液和血清中铁蛋白的相关性,以及通过总蛋白校正铁蛋白值的可能影响。检测了来自健康(n=30)和 COVID-19(n=65)患者(根据是否需要鼻导管吸氧或辅助呼吸,疾病严重程度分为重症[n=18]和轻症[n=47])的唾液中铁蛋白。还检测了来自健康和 COVID-19 患者配对的血清和唾液样本(n=32)中的铁蛋白。除添加 0.5%SDS 外,评估的灭活方案不会影响检测结果。与健康对照组(4.21μg/L;2.6-8.08μg/L)相比,COVID-19 患者唾液中的铁蛋白(中位数;25%-75%分位数)显著更高(27.75μg/L;9.77-52.2μg/L)。重症 COVID-19 患者的唾液铁蛋白值(48.7μg/L;18.7-53.9)高于轻症患者(15.5μg/L;5.28-41.3μg/L)。血清和唾液中的铁蛋白之间存在显著相关性(r=0.425;<0.001)。COVID-19 患者的血清和唾液中的铁蛋白水平较高,且症状最严重的患者铁蛋白值最高。总之,唾液铁蛋白可能成为评估 COVID-19 患者严重程度的生物标志物。